MLYS Mineralys Therapeutics Forecast, Technical & Fundamental Analysis
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone... Show more
MLYS is expected to report earnings to rise 459.57% to -263 cents per share on August 18
Q2'26
Est.
$-2.63
Q1'26
Beat
by $0.34
Q4'25
Beat
by $0.54
Q3'25
Beat
by $0.44
Q2'25
Beat
by $0.40
The last earnings report on May 06 showed earnings per share of -46 cents, beating the estimate of -81 cents. With 8.17M shares outstanding, the current market capitalization sits at 2.38B.
A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with IONS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then IONS could also see price increases.
Momentum Indicator for MLYS turns positive, indicating new upward trend
MLYS saw its Momentum Indicator move above the 0 level on May 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 52 similar instances where the indicator turned positive. In of the 52 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MLYS just turned positive on May 22, 2026. Looking at past instances where MLYS's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
MLYS moved above its 50-day moving average on May 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MLYS advanced for three days, in of 171 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 115 cases where MLYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.238) is normal, around the industry mean (21.430). P/E Ratio (0.000) is within average values for comparable stocks, (35.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). MLYS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (362.782).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MLYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
